Clinical Trial to Compare the Pharmacokinetics of DP-R208
NCT ID: NCT02707224
Last Updated: 2016-03-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
40 participants
INTERVENTIONAL
2015-01-31
2015-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Compare the Safety and Pharmacokinetics of CKD-330 8/5mg With Coadministration of the Two Separate Drugs
NCT02548286
CKD-330 Drug-Drug Interaction Study (Candesartan)
NCT02064621
Exploratory Trial to Evaluate the Pharmacokinetic Properties and Safety of CKD-828 in Healthy Subjects
NCT05540912
A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension
NCT02059616
A Relative Bioavailability Study of a Fixed Dose Combination (FDC) Tablets of GSK587323
NCT02094924
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
combination dose of Candesartan cilexetil and Rosuvastatin and DP-R208 in order
DP-R208
Investigational product is prescribed to all of randomized subjects
Candesartan cilexetil
Investigational product is prescribed to all of randomized subjects
Rosuvastatin
Investigational product is prescribed to all of randomized subjects
Group B
DP-R208 and combination dose of Candesartan cilexetil and Rosuvastatin in order
DP-R208
Investigational product is prescribed to all of randomized subjects
Candesartan cilexetil
Investigational product is prescribed to all of randomized subjects
Rosuvastatin
Investigational product is prescribed to all of randomized subjects
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DP-R208
Investigational product is prescribed to all of randomized subjects
Candesartan cilexetil
Investigational product is prescribed to all of randomized subjects
Rosuvastatin
Investigational product is prescribed to all of randomized subjects
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* signed the informed consent form prior to the study participation
Exclusion Criteria
* Previously donate whole blood within 60 days or component blood within 14 days
* Clinically significant allergic disease
* Taken IP in other trial within 90 days
* An impossible one who participates in clinical trial by investigator's decision including laboratory test result
19 Years
55 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alvogen Korea
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Min-Gul Kim, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Chonbuk National University Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DP-CTR208-I-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.